{{citations missing|date=September 2009}}
{{Drugbox
| verifiedrevid = 470631324
| IUPAC_name = (1''S'',2''S'',3''R'',4''S'',5''S'')-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
| image = Voglibose structure.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|voglibose}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 83480-29-9
| ATC_prefix = A10
| ATC_suffix = BF03
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 476960
| PubChem = 444020
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04878
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 392046
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S77P977AG8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01665

<!--Chemical data-->
| C=10 | H=21 | N=1 | O=7 
| molecular_weight = 267.28 g/mol
| smiles = OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
| InChI = 1/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
| InChIKey = FZNCGRZWXLXZSZ-CIQUZCHMBI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FZNCGRZWXLXZSZ-CIQUZCHMSA-N
}}
'''Voglibose''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]], trade name '''Voglib''', marketed by Mascot Health Series) is an [[alpha-glucosidase inhibitor]] used for lowering post-prandial blood glucose levels in people with [[diabetes mellitus]]. Voglibose delays the absorption of glucose thereby reduces the risk of macrovascular complications. Voglibose is a research product of Takeda Pharma, a Japan based company.

[[Postprandial]] [[hyperglycemia]] (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, [[acarbose]], [[miglitol]] and voglibose, of which voglibose is the newest. Voglibose scores over both acarbose and miglitol in terms of side effect profile. But acarbose has an edge over voglibose in terms of efficacy ([[Fasting plasma glucose|FPG]], PPHG, [[Glycated hemoglobin|HBA<sub>1c</sub>]]).

There are several trials supporting the use of voglibose in the management of PPHG. Also, it has been established that it is PPHG, not FPG, which is the marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and voglibose is indicated for the management of PPHG.

==External links==
* [http://www.medicalnewstoday.com/medicalnews.php?newsid=36827 Ranbaxy announcement]

{{Oral hypoglycemics and insulin analogs}}

[[Category:Alpha-glucosidase inhibitors]]
[[Category:Amino sugars]]


{{gastrointestinal-drug-stub}}